SLAM
PTGX icon

Swiss Life Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Swiss Life Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$417K Buy
3,403
+299
+10% +$31.2K ﹤0.01% 1071
2026
Q1 		$327K Buy
3,104
+673
+28% +$59.6K ﹤0.01% 1083
2025
Q4 		$212K Buy
+2,431
New +$199K ﹤0.01% 1242

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Swiss Life Asset Management's PTGX Position: Q2 2026 in Review

Swiss Life Asset Management increased its Protagonist Therapeutics (PTGX) stake by 9.6% in Q2 2026, buying an estimated $31.2K and bringing the position to 3,403 shares worth $417K. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

Swiss Life Asset Management first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. 224 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Swiss Life Asset Management held 3,403 shares of Protagonist Therapeutics worth $417K as of Q2 2026.
  • Swiss Life Asset Management bought 299 Protagonist Therapeutics shares in Q2 2026, an estimated $31.2K.
  • Protagonist Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1071 holding.
  • Swiss Life Asset Management first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 224 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.